From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: Chris is right about Whitbread as we hit 24% of Woodlarks target

By Tom Winnifrith | Thursday 21 May 2020


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Over the weekend I hope to bring you photos of a semi complete strawberry patch here at the Welsh Hovel and also of my first long training walk for Woodlarks. I donated £1000 yesterday and young Steve Moore also made a generous gift so we are now at 24% of the £48,000 we need to ensure Woodlarks survives. Please donate HERE. In the podcast I look at Whitbread (WTB), Catenae (CTEA) and at where we are in the gold shares buying cycle, referring to three I own and am very excited: Bluebird Merchant (BMV), Kefi (KEFI ) - no sniggering at the back please - and Xtract (XTR). Again no sniggering.

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:47:54